secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytosorbents Corp (CTSO)
CIK:        0001175151
Form:       8-K
Filed at:   2026-06-25T13:26:59+00:00
Accession:  0001104659-26-077584
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytoSorbents schedules two FDA pre-submission meetings for ticagrelor and DOAC programs in August 2026
--------------------------------------------------------------------------------

- Two pre-submission meetings with FDA scheduled for August 2026.
- Meetings will cover CytoSorbents' ticagrelor and DOAC programs.
- Announcement made at 2026 Life Sciences Forum; no financial impact disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1175151/000110465926077584/0001104659-26-077584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1175151/000110465926077584/tm2618977d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-077584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer